WALTHAM, Mass. — November 4, 2025 — Leads & Copy — Verastem Oncology (Nasdaq: VSTM) has released business updates and financial results for Q3 2025, which ended September 30.
Net revenue exceeded expectations at over $11 million, driven by the accelerated approval and launch of AVMAPKI FAKZYNJA CO-PACK. The first full quarter since the launch demonstrated the strength of the company’s growing commercial business with consistent adoption by academic and community oncologists.
In the ongoing Phase 3 RAMP 301 confirmatory trial, planned enrollment of the targeted 270 patients was completed a full quarter early. An Independent Data Monitoring Committee (IDMC) recommended a one-time increase of 29 patients across KRAS mutation status. Preliminary safety and efficacy data from the Phase 2 RAMP 201J trial in Japan was accepted as an E-Poster (EP228/ #371) at the International Gynecologic Cancer Society (IGCS) 2025 Annual Meeting. Additional data, including efficacy (response rates) and updated safety will be available on November 5, 2025, when the embargo lifts.
A preliminary update on the Phase 1/2a monotherapy dose escalation trial of VS-7375 in patients with previously treated advanced KRAS G12D mutant solid tumors was announced on Oct. 23, 2025. In the study, VS-7375 cleared both the 400 mg daily (QD) and the 600 mg QD monotherapy doses with no dose-limiting toxicities (DLTs) observed. GenFleet Therapeutics reported an overall response rate (ORR) of 41% was achieved at the monotherapy recommended Phase 2 dose (RP2D) of 600 mg QD. At the RP2D of 600 mg QD, the ORR was 68.8% (11/16) (both confirmed and unconfirmed) and the DCR was 93.8% (15/16) in the GenFleet’s Phase 1/2 study of GFH375 in China. The Company also announced it has initiated patient enrollment for the first dose escalation combination cohort evaluating VS-7375 with cetuximab in patients with advanced solid tumors, including colorectal cancer.
Verastem Oncology ended the third quarter of 2025 with cash, cash equivalents and investments of $137.7 million. With existing cash, product revenue, and exercise of cash warrants, the Company has expected cash runway into the second half of 2026.
Dan Paterson, president and chief executive officer of Verastem Oncology, commented on the results and ongoing programs.
Conference call today at 8:00 a.m. ET to review the third quarter 2025 financial results and recent business updates. To access the conference call, please dial (888) 596-4144 (U.S.) or (646) 968-2525 (international) and enter the passcode 8194537.
No contact person was named in the release.
Source: Verastem Oncology
